On July 20, the Oncologic Drugs Advisory Committee (ODAC) of the FDA’s Center for Drug Evaluation and Research voted 12 to 1 to recommend against the use of bevacizumab (Avastin) in combination with chemotherapy for the first-line treatment of metastatic breast cancer. The FDA granted accelerated approval for bevacizumab in March 2008 for this indication, but it was contingent on additional positive results from ongoing clinical trials.
At last week’s meeting, committee members reviewed mature results from those trials, and the trials failed to confirm the data that led to the accelerated approval. Read more > >
A MESSAGE TO READERS
Sun Safety Featured on Cancer.gov
Skin cancer is the most common form of cancer in the United States, with more than 1 million cases diagnosed each year. This month, the NCI Web site highlights the importance of protecting yourself from the sun and other sources of ultraviolet light. Read more about skin cancer resources and research online./div>
- Plan to Attend NCI’s Clinical Proteomic Technologies for Cancer Meeting
- Register Now for caBIG Annual Meeting in September
- Join Leaders in the Field of Cancer and Inflammation at September Conference
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit .
NCI Cancer Bulletin staff can be reached at firstname.lastname@example.org.